Table 6 PE investment cases in 2012
From: Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
Enterprises | Amount | Investor | Issue time |
|---|---|---|---|
Nantong Novast Pharmaceuticals Co., Ltd. | 20 million USD | Lilly Asia Ventures | 13/6/2012 |
Gansu Longshen Rongfa Pharmaceutical Co., Ltd. | 2.9 million USD | Genertec Investment Managers Ltd. | 29/3/2012 |
Luye Pharma Group Ltd | N/A | CDH Investments; CITIC Private Equity Funds Management Co., Ltd.; New Horizon | 3/2/2012 |
Shaanxi Bicon Pharmaceutical Co., Ltd. | 250 million USD | Pacific Alliance Group | 28/2/2012 |
Kaifeng Pharmaceutical (Group) Co., Ltd. | 14.7 million USD | N/A | 20/2/2012 |